The World Health Organisation (WHO) said on Tuesday that it has approved a Covid-19 vaccine made by drugmaker Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in poor countries. A WHO emergency listing is a signal to national regulators on a product’s safety and efficacy. It will also allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries, which faces major supply problems due to an Indian export suspension. The independent panel of experts said in a statement it recommended Sinovac’s vaccine for adults over 18, with a second dose 2-4 weeks later. There was no upper age limit as data suggested it is likely to have a protective effect in older people. The WHO’s technical advisory group, which began meeting on May 5, took the decision after reviewing the latest clinical data on the Sinovac vaccine’s safety and efficacy as well as the company’s manufacturing practices. Branded CoronaVac in some regions, it is the second Chinese developed vaccine to win such a WHO listing to combat Covid-19, after the May 7 approval of a shot developed by state-backed Sinopharm. A third Chinese vaccine, produced by CanSino Biologics, has submitted clinical trial data, but no WHO review has been scheduled.